Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Surufatinib and Tislelizumab in Advanced Solid Tumors
NCT04579757Phase 2Terminated
- Sponsor
- HUTCHMED
- Start
- Mar 2021
- Primary completion
- Apr 2024
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of surufatinib in colorectal cancer (CRC), Neuroendocrine Neoplasm (NEN), small cell lung cancer (SCLC), gastric cancer (GC), soft tissue sarcoma (STS), sponsored by HUTCHMED. Started Mar 2021; status: terminated.
02
Drugs
surufatinib
03
Conditions
colorectal cancer (CRC)Neuroendocrine Neoplasm (NEN)small cell lung cancer (SCLC)gastric cancer (GC)soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT04579757.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04579757.